2006
DOI: 10.1001/archderm.142.1.115
|View full text |Cite
|
Sign up to set email alerts
|

Infliximab-Induced Lupus Erythematosus Tumidus in a Patient With Rheumatoid Arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
25
0
1

Year Published

2006
2006
2021
2021

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 41 publications
(26 citation statements)
references
References 6 publications
0
25
0
1
Order By: Relevance
“…Until recently, there have been only two reports of drugassociated LET [16,17]. The causal association between bortezomib and induction of LET in this case was underlined by the pattern of a resolving rash following removal of the drug while other parameters (medications, lifestyle, laboratory parameters, etc.)…”
mentioning
confidence: 72%
“…Until recently, there have been only two reports of drugassociated LET [16,17]. The causal association between bortezomib and induction of LET in this case was underlined by the pattern of a resolving rash following removal of the drug while other parameters (medications, lifestyle, laboratory parameters, etc.)…”
mentioning
confidence: 72%
“…LET completely resolved after discontinuing therapy and, interestingly, did not relapse after administering another TNF-alfa antagonist (etanercept). 159 In another study, 4 of 5 patients with infliximab-induced lupus-like syndrome tolerated an alternative TNF-alfa inhibitor (3 patients, adalimumab; 1 patient, etanercept). 150 Etanercept.…”
Section: Tnf-alfa Antagonistsmentioning
confidence: 99%
“…Drug-induced LET has been reported in 3 cases. One patient with RA developed LET after 13 infusions of infliximab 7 ; the second case of LET was induced by thiazide diuretics; and the third occurred as a manifestation of immune restoration following initiation of highly active antiretroviral therapy (HAART) 8 . The drugs noted in the second and third case reports were not used in our case.…”
Section: To the Editormentioning
confidence: 99%